428 Shares in Illumina, Inc. (ILMN) Acquired by SRS Capital Advisors Inc.

SRS Capital Advisors Inc. purchased a new stake in Illumina, Inc. (NASDAQ:ILMN) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 428 shares of the life sciences company’s stock, valued at approximately $157,000.

Other institutional investors have also recently bought and sold shares of the company. Janney Montgomery Scott LLC raised its holdings in Illumina by 10.0% in the 2nd quarter. Janney Montgomery Scott LLC now owns 23,555 shares of the life sciences company’s stock valued at $6,579,000 after acquiring an additional 2,141 shares in the last quarter. Standard Life Aberdeen plc raised its holdings in shares of Illumina by 31.1% in the 2nd quarter. Standard Life Aberdeen plc now owns 34,546 shares of the life sciences company’s stock worth $9,650,000 after buying an additional 8,199 shares in the last quarter. Waters Parkerson & CO. LLC acquired a new position in shares of Illumina in the 2nd quarter worth approximately $223,000. Bank of Nova Scotia raised its holdings in shares of Illumina by 216.4% in the 2nd quarter. Bank of Nova Scotia now owns 59,185 shares of the life sciences company’s stock worth $16,529,000 after buying an additional 40,478 shares in the last quarter. Finally, Eqis Capital Management Inc. increased its holdings in Illumina by 40.7% during the 2nd quarter. Eqis Capital Management Inc. now owns 9,676 shares of the life sciences company’s stock valued at $2,702,000 after purchasing an additional 2,797 shares in the last quarter. 89.90% of the stock is owned by hedge funds and other institutional investors.

In other Illumina news, Director Robert S. Epstein sold 1,346 shares of the stock in a transaction on Friday, September 7th. The stock was sold at an average price of $345.14, for a total value of $464,558.44. Following the transaction, the director now directly owns 7,139 shares in the company, valued at approximately $2,463,954.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Francis A. Desouza sold 2,100 shares of the stock in a transaction on Monday, October 1st. The shares were sold at an average price of $369.61, for a total value of $776,181.00. The disclosure for this sale can be found here. Insiders sold a total of 53,464 shares of company stock worth $17,883,331 over the last quarter. Corporate insiders own 0.54% of the company’s stock.

Shares of ILMN opened at $329.25 on Friday. The firm has a market capitalization of $50.37 billion, a price-to-earnings ratio of 82.31, a PEG ratio of 2.54 and a beta of 1.07. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.24 and a current ratio of 2.46. Illumina, Inc. has a 52 week low of $203.83 and a 52 week high of $372.61.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, October 23rd. The life sciences company reported $1.52 EPS for the quarter, beating the Zacks’ consensus estimate of $1.26 by $0.26. The firm had revenue of $853.00 million for the quarter, compared to analyst estimates of $825.65 million. Illumina had a return on equity of 27.10% and a net margin of 21.09%. The business’s quarterly revenue was up 19.5% compared to the same quarter last year. During the same period last year, the company earned $1.11 EPS. Analysts forecast that Illumina, Inc. will post 5.75 EPS for the current year.

A number of research firms recently weighed in on ILMN. Piper Jaffray Companies raised their price target on Illumina to $380.00 and gave the company an “overweight” rating in a report on Tuesday, October 2nd. BidaskClub cut Illumina from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 4th. Cowen raised their price target on Illumina from $315.00 to $400.00 and gave the company a “positive” rating in a report on Thursday, September 6th. Argus set a $372.00 price target on Illumina and gave the company a “buy” rating in a report on Friday, August 10th. Finally, Morgan Stanley raised Illumina from an “underweight” rating to an “equal weight” rating and raised their price target for the company from $210.00 to $320.00 in a report on Tuesday, August 7th. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $330.94.

COPYRIGHT VIOLATION NOTICE: This story was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://sportsperspectives.com/2018/11/10/428-shares-in-illumina-inc-ilmn-acquired-by-srs-capital-advisors-inc.html.

Illumina Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Further Reading: Trading Strategy Methods for Individual Investors

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply